ZIVO vs. AQST, GOSS, CADL, ATYR, IMMP, OLMA, KRRO, NMRA, YMAB, and KOD
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Aquestive Therapeutics (AQST), Gossamer Bio (GOSS), Candel Therapeutics (CADL), Atyr PHARMA (ATYR), Immutep (IMMP), Olema Pharmaceuticals (OLMA), Korro Bio (KRRO), Neumora Therapeutics (NMRA), Y-mAbs Therapeutics (YMAB), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.
ZIVO Bioscience vs.
ZIVO Bioscience (NASDAQ:ZIVO) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability.
Aquestive Therapeutics received 113 more outperform votes than ZIVO Bioscience when rated by MarketBeat users. Likewise, 68.17% of users gave Aquestive Therapeutics an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote.
In the previous week, Aquestive Therapeutics had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Aquestive Therapeutics and 0 mentions for ZIVO Bioscience. Aquestive Therapeutics' average media sentiment score of 1.30 beat ZIVO Bioscience's score of 0.00 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.
Aquestive Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 265.45%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than ZIVO Bioscience.
ZIVO Bioscience has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 2.67, meaning that its share price is 167% more volatile than the S&P 500.
12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 21.5% of ZIVO Bioscience shares are owned by insiders. Comparatively, 7.9% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ZIVO Bioscience has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -59.75%.
ZIVO Bioscience has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.
Summary
Aquestive Therapeutics beats ZIVO Bioscience on 13 of the 18 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:ZIVO) was last updated on 2/22/2025 by MarketBeat.com Staff
